17366438|t|[Pharmacotherapy--physostigmine administered post-operatively].
17366438|a|The central anticholinergic syndrome should be considered in patients with altered mental status following anaesthesia. Physostigmine, a reversible acetylcholinesterase inhibitor, is a first-line medicament for the therapy of the central anticholinergic syndrome. Physostigmine crosses the blood-brain barrier and elevates acetylcholine levels in the brain. For prevention of postanaesthetic shivering, for treatment of intoxications and postoperative pain, and for patients suspected of having antimuscarinic delirium physostigmine is also indicated.
17366438	18	31	physostigmine	Chemical	MESH:D010830
17366438	76	100	anticholinergic syndrome	Disease	MESH:D064807
17366438	125	133	patients	Species	9606
17366438	184	197	Physostigmine	Chemical	MESH:D010830
17366438	212	232	acetylcholinesterase	Gene	43
17366438	302	326	anticholinergic syndrome	Disease	MESH:D064807
17366438	328	341	Physostigmine	Chemical	MESH:D010830
17366438	387	400	acetylcholine	Chemical	MESH:D000109
17366438	502	520	postoperative pain	Disease	MESH:D010149
17366438	530	538	patients	Species	9606
17366438	574	582	delirium	Disease	MESH:D003693
17366438	583	596	physostigmine	Chemical	MESH:D010830
17366438	Negative_Correlation	MESH:D010830	43
17366438	Negative_Correlation	MESH:D010830	MESH:D064807
17366438	Negative_Correlation	MESH:D010830	MESH:D010149
17366438	Positive_Correlation	MESH:D000109	MESH:D010830
17366438	Negative_Correlation	MESH:D010830	MESH:D003693

